Sigifredo Pedraza-Sánchez

Sigifredo Pedraza-Sánchez

Auto-generated profile, based on publicly available information

Sigifredo Pedraza-Sánchez

Unit of Biochemistry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico City, 14080, Mexico

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in Medicine
Verified
Journal Article
Closed access
LBLudovic de Beaucoudrey
Ludovic de Beaucoudrey
ASArina Samarina
Arina Samarina
JBJacinta Bustamante
Jacinta Bustamante
ACAurélie Cobat
Aurélie Cobat
SBStephanie Boisson-Dupuis
Stephanie Boisson-Dupuis
JCJean-Laurent Casanova
Jean-Laurent Casanova
Interleukin-12 receptor β1 (IL-12Rβ1) deficiency is the most common form of Mendelian susceptibility to mycobacterial disease (MSMD). We undertook an international survey of 141 patients from 102 kindreds in 30 countries. Among 102 probands, the first infection occurred at a mean age of 2.4 years. In 78 patients, this infection was caused by Bacille Calmette-Guérin (BCG; n = 65), environmental mycobacteria (EM; also known as atypical or nontuberculous mycobacteria) (n = 9) or Mycobacterium tuberculosis (n = 4). Twenty-two of the remaining 24 probands initially presented with nontyphoidal, extraintestinal salmonellosis. Twenty of the 29 genetically affected sibs displayed clinical signs (69%); however 8 remained asymptomatic (27%). Nine nongenotyped sibs with symptoms died. Recurrent BCG infection was diagnosed in 15 cases, recurrent EM in 3 cases, recurrent salmonellosis in 22 patients. Ninety of the 132 symptomatic patients had infections with a single microorganism. Multiple infections were diagnosed in 40 cases, with combined mycobacteriosis and salmonellosis in 36 individuals. BCG disease strongly protected against subsequent EM disease (p = 0.00008). Various other infectious diseases occurred, albeit each rarely, yet candidiasis was reported in 33 of the patients (23%). Ninety-nine patients (70%) survived, with a mean age at last follow-up visit of 12.7 years ± 9.8 years (range, 0.5-46.4 yr). IL-12Rβ1 deficiency is characterized by childhood-onset mycobacteriosis and salmonellosis, rare recurrences of mycobacterial disease, and more frequent recurrence of salmonellosis. The condition has higher clinical penetrance, broader susceptibility to infections, and less favorable outcome than previously thought. Abbreviations: BCG = Bacille Calmette-Guérin, CI = confidence interval, EBV-B cell lines = Epstein-Barr virus-transformed lymphoblastoid cell lines, ELISA = enzyme-linked immunosorbent assay, EM= environmental mycobacteria (nontuberculous mycobacteria), FBS = fetal bovine serum, FD = fibronectin domain, IFNGR = interferon-γ receptor, IL12B = interleukin-12B, IL-12Rβ1 = interleukin-12 receptor beta 1 chain, MSMD = Mendelian susceptibility tomycobacterial disease, NEMO = nuclear factor-κB essential modulator, PBS = phosphate-buffered saline, PCR = polymerase chain reaction, PHA = phytohemagglutinin, PR = present report, STAT1 = Signal transducer and activator of transcription 1.

1 July 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
FCFrancesca Conti
Francesca Conti
SLSaul Oswaldo Lugo-Reyes
Saul Oswaldo Lugo-Reyes
LGLizbeth Blancas Galicia
Lizbeth Blancas Galicia
JHJianxin He
Jianxin He
GAGüzide Aksu
Güzide Aksu
JBJacinta Bustamante
Jacinta Bustamante

1 November 2013 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MOMonia Ouederni
Monia Ouederni
OSOzden Sanal
Ozden Sanal
AIAydan Ikincioğullari
Aydan Ikincioğullari
ITIlhan Tezcan
Ilhan Tezcan
FDFigen Dogu
Figen Dogu
CRCarlos Rodríguez-Gallego
Carlos Rodríguez-Gallego
Background. Interleukin 12Rβ1 (IL-12Rβ1)–deficient patients are prone to clinical disease caused by mycobacteria, Salmonella, and other intramacrophagic pathogens, probably because of impaired interleukin 12–dependent interferon γ production. About 25% of patients also display mucocutaneous candidiasis, probably owing to impaired interleukin 23–dependent interleukin 17 immunity. The clinical features and outcome of candidiasis in these patients have not been described before, to our knowledge. We report here the clinical signs of candidiasis in 35 patients with IL-12Rβ1 deficiency. Results. Most (n = 71) of the 76 episodes of candidiasis were mucocutaneous. Isolated oropharyngeal candidiasis (OPC) was the most common presentation (59 episodes, 34 patients) and was recurrent or persistent in 26 patients. Esophageal candidiasis (n = 7) was associated with proven OPC in 2 episodes, and cutaneous candidiasis (n = 2) with OPC in 1 patient, whereas isolated vulvovaginal candidiasis (VVC; n = 3) was not. Five episodes of proven invasive candidiasis were documented in 4 patients; 1 of these episodes was community acquired in the absence of any other comorbid condition. The first episode of candidiasis occurred earlier in life (median age±standard deviation, 1.5 ± 7.87 years) than infections with environmental mycobacteria (4.29 ± 11.9 years), Mycobacterium tuberculosis (4 ± 3.12 years), or Salmonella species (4.58 ± 4.17 years) or other rare infections (3 ± 11.67 years). Candidiasis was the first documented infection in 19 of the 35 patients, despite the vaccination of 10 of these 19 patients with live bacille Calmette-Guérin. Conclusions. Patients who are deficient in IL-12Rβ1 may have candidiasis, usually mucocutaneous, which is frequently recurrent or persistent. Candidiasis may be the first clinical manifestation in these patients.

10 February 2020 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
LGLizbeth Blancas Galicia
Lizbeth Blancas Galicia
ESEros Santos-Chávez
Eros Santos-Chávez
CDCaroline Deswarte
Caroline Deswarte
QMQuentin Mignac
Quentin Mignac
Isabel Medina-VeraIsabel Medina-Vera
Isabel Medina-Vera
JBJacinta Bustamante
Jacinta Bustamante

11 July 2018 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
JRJérémie Rosain
Jérémie Rosain
COCarmen Oleaga-Quintas
Carmen Oleaga-Quintas
CDCaroline Deswarte
Caroline Deswarte
HVHannah Verdin
Hannah Verdin
SMStéphane Marot
Stéphane Marot
JBJacinta Bustamante
Jacinta Bustamante

10 April 2019 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
IMIsela Martínez-Reza
Isela Martínez-Reza
Lorenza DiazLorenza Diaz
Lorenza Diaz
DBDavid Barrera
David Barrera
MSMariana Segovia-Mendoza
Mariana Segovia-Mendoza
SPSigifredo Pedraza-Sánchez
Sigifredo Pedraza-Sánchez
RGRocío García-Becerra
Rocío García-Becerra
Triple-negative breast cancer (TNBC) is one of the most aggressive tumors, with poor prognosis and high metastatic capacity. The aggressive behavior may involve inflammatory processes characterized by deregulation of molecules related to the immunological responses in which interleukin-1β(IL-1β) and tumor necrosis factor-α(TNF-α) are involved. It is known that calcitriol, the active vitamin D metabolite, modulates the synthesis of immunological mediators; however, its role in the regulation of IL-1βand TNF-αin TNBC has been scarcely studied. In the present study, we showed that TNBC cell lines SUM-229PE and HCC1806 expressed vitamin D, IL-1β, and TNF-αreceptors. Moreover, calcitriol, its analogue EB1089, IL-1β, and TNF-αinhibited cell proliferation. In addition, we showed that synthesis of both IL-1βand TNF-αwas stimulated by calcitriol and its analogue. Interestingly, the antiproliferative activity of calcitriol was significantly abrogated when the cells were treated with anti-IL-1βreceptor 1 (IL-1R1) and anti-TNF-αreceptor type 1 (TNFR1) antibodies. Furthermore, the combination of calcitriol with TNF-αresulted in a greater antiproliferative effect than either agent alone, in the two TNBC cell lines and an estrogen receptor-positive cell line. In summary, this study demonstrated that calcitriol exerted its antiproliferative effects in part by inducing the synthesis of IL-1βand TNF-αthrough IL-1R1 and TNFR1, respectively, in TNBC cells, highlighting immunomodulatory and antiproliferative functions of calcitriol in TNBC tumors.